<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179631</url>
  </required_header>
  <id_info>
    <org_study_id>PTC124-GD-041-DMD</org_study_id>
    <nct_id>NCT03179631</nct_id>
  </id_info>
  <brief_title>Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Phase 3,Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a long-term study of ataluren in patients with nonsense mutation Duchenne
      muscular dystrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, 72-week study followed by a
      72-week open-label period. The purpose is to characterize the long-term effects of
      ataluren-mediated dystrophin restoration on disease progression. Patients will be randomized
      in a 1:1 ratio to ataluren or placebo. Patients will receive blinded study drug TID at
      morning, midday, and evening for 72 weeks, after which all patients will receive open-label
      ataluren for an additional 72 weeks (144 weeks in total). Study assessments will be performed
      at clinic visits every 12 weeks during the double-blind period and every 24 weeks during the
      open-label period. The total sample size of ~250 subjects will include ~160 subjects who meet
      the criteria for inclusion in the primary analysis population (age 7 to 16 years old,
      baseline 6MWD &gt;=300 meters, supine to stand &gt;=5 seconds). The study will be conducted in the
      United States and other countries around the world.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study describes the randomized, double-blind, placebo-controlled, 72-week study and its 72-week open-label extension</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A randomized, double-blind, placebo-controlled,72-week study and its 72-week open-label extension</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>6- Minute Walk Test</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timed Function Tests</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>North Star Ambulatory Assessment</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of Upper Limb (in patients &gt;=7 years old at baseline)</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myometry (in patients &lt;7 years old at baseline)</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging (MRI) (at pre-qualified sites)</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>72 weels</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ataluren safety profile characterized by adverse events and abnormalities of laboratory tests, vital signs, physical examinations, or electrocardiograms</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <condition>Muscular Dystrophies</condition>
  <condition>Muscular Disorders, Atrophic</condition>
  <condition>Muscular Diseases</condition>
  <condition>Musculoskeletal Disease</condition>
  <condition>Neuromuscular Diseases</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Genetic Diseases, X-Linked</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <arm_group>
    <arm_group_label>Ataluren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10, 10, 20 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10, 10, 20 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ataluren</intervention_name>
    <description>10, 10, 20 mg/kg</description>
    <arm_group_label>Ataluren</arm_group_label>
    <other_name>PTC124</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>10, 10, 20 mg/kg</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria -

          -  Male sex.

          -  Age ≥5 years.

          -  Phenotypic evidence of DMD

          -  Nonsense point mutation in the dystrophin gene

          -  Use of systemic corticosteroids (prednisone/prednisolone or deflazacort)for a minimum
             of 12 months immediately prior to start of study treatment, with no significant change
             in dosage or dosing regimen for a minimum of 3 months immediately prior to start of
             study treatment

          -  6MWD ≥150 meters

          -  Ability to perform timed function tests within 30 seconds

          -  Willingness and ability to comply with scheduled visits, drug administration plan,
             study procedures, laboratory tests, and study restrictions.

        Exclusion Criteria:

          -  Any change in prophylaxis treatment for cardiomyopathy within 1 month prior to start
             of study treatment.

          -  Prior or ongoing intravenous (IV) aminoglycoside or IV vancomycin therapy.

          -  Prior or ongoing therapy with ataluren.

          -  Known hypersensitivity to any of the ingredients or excipients of the study drug

          -  Exposure to another investigational drug within 6 months prior to start of study
             treatment, or ongoing participation in any interventional clinical trial.

          -  History of major surgical procedure within 12 weeks prior to start of study treatment,
             or expectation of major surgical procedure during the 72-week placebo-controlled
             treatment period.

          -  Requirement for daytime ventilator assistance or any use of invasive mechanical
             ventilation via tracheostomy.

          -  Uncontrolled clinical symptoms and signs of congestive heart failure

          -  Elevated serum creatinine or cystatin C at screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Bibbiani, MD</last_name>
    <role>Study Director</role>
    <affiliation>PTC Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Frances Harmon</last_name>
    <phone>908-912-9256</phone>
    <email>mharmon@ptcbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PTC Medical Information</last_name>
    <email>medinfo@ptcbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn McLaughlin Savage</last_name>
      <phone>650-206-3178</phone>
      <email>cjmclaug@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Novagrami George</last_name>
      <phone>203-785-5977</phone>
      <email>novagrami.george@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Cristian Ionita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiley Higgs</last_name>
      <phone>913-945-9922</phone>
      <email>ksims2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Statland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan - CS Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas L Harris</last_name>
      <phone>734-998-9972</phone>
      <email>harrisnl@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Neil Knierbein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamal Ameli</last_name>
      <phone>313-745-0627</phone>
      <email>Jameli@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Huiyuan Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya Burlakova</last_name>
      <phone>612-626-4690</phone>
      <email>burla019@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Karachunski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Physicians &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ameneh Onativia</last_name>
      <phone>212-342-3679</phone>
      <email>am2959@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Darryl De Vivo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Wagner</last_name>
      <phone>513-803-9036</phone>
      <email>sarah.wagner@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Cuixia Tian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Black</last_name>
      <phone>971-282-4616</phone>
      <email>cablack@shrinenet.org</email>
    </contact>
    <investigator>
      <last_name>Erika Finanger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Floyd Jones</last_name>
      <phone>210-567-8222</phone>
      <email>JonesFA@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Ratna Bhavaraju-Sanka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittney Holmberg</last_name>
      <phone>801-585-9055</phone>
      <email>brittneyh@genetics.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Russell Butterfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrie Karras Conklin</last_name>
      <phone>757-469-9123</phone>
      <email>terrie.conklin@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Crystal Proud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Christensen</last_name>
      <phone>206-987-5433</phone>
      <email>muscleresearch@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Susan Apkon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prevea Clinic, Inc</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Quinnell</last_name>
      <phone>920-272-1044</phone>
      <email>cindy.quinnell@prevea.com</email>
    </contact>
    <investigator>
      <last_name>Terence Edgar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Childrens Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Gan</last_name>
      <phone>+61 2 9845 0172</phone>
      <email>lin.gan@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Kristi Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Childrens Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jemima Mitchell</last_name>
      <phone>+61 39936 6157</phone>
      <email>jemima.mitchell@rch.org.au</email>
    </contact>
    <investigator>
      <last_name>Monique Ryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMHAT Aleksandrovska - Clinic of Neurology Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teodora Chamova</last_name>
      <phone>35 988 980 2252</phone>
      <email>teodoratch@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Ivaylo Tournev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMHAT Sofiamed</name>
      <address>
        <city>Sofia</city>
        <zip>1793</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Tzolova-Stamenova</last_name>
      <phone>359 888 771 652</phone>
      <email>tzolova.elena@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Velina Guergueltcheva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>SAR</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Mok</last_name>
      <phone>+852 2255 4538</phone>
      <email>moksp@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Sophelia Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Panchshil Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radhika Patel</last_name>
      <phone>07927506336</phone>
      <email>radhikakikani9@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Siddharth Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneagles Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apurba Paul</last_name>
      <phone>+91 33 2320 3040</phone>
      <email>apu_hm@rediffmail.com</email>
    </contact>
    <investigator>
      <last_name>Arijit Chattopadhyay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Shimizu</last_name>
      <phone>+81-051-858-7215</phone>
      <email>crnshi3@med.nagoya-cu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Shinji Saitoh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Toneyama National Hospital</name>
      <address>
        <city>Toyonaka-shi</city>
        <state>Osaka</state>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miyuki Kanazawa</last_name>
      <phone>+81-6-6853-2001</phone>
      <email>mkanazawa@toneyama.go.jp</email>
    </contact>
    <investigator>
      <last_name>Tsuyoshi Matsumura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Yonago</city>
        <state>Tottori</state>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiko Hashida</last_name>
      <phone>+81-859-38-6946</phone>
      <email>s.hashida@med.tottori-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Yoshihiro Maegaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Hyōgo</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saori Ebisuya</last_name>
      <phone>+81-798-45-6006</phone>
      <email>ebi@hyo-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Yasuhiro Takeshima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukiko Futa</last_name>
      <phone>+81-96-373-5842</phone>
      <email>yukiko-futa@kuh.kumamoto-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Shiro Ozasa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Tokyo</city>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayo Katsumura</last_name>
      <phone>+81-42-341-2711</phone>
      <email>katsumura@ncnp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Hirofumi Komaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnamdo</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiyung Jeong</last_name>
      <email>jiyoungaci@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jin-Hong Shin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miae Kim</last_name>
      <phone>82-2-6072-5185</phone>
      <email>selly-kma@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Jong-Hee Chae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuala Lumpur Hospital - Pediatrics Neurology</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rusiani Binti Ab Rahman</last_name>
      <phone>+6016 2338047</phone>
      <email>rusiani1981@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Teik Beng Khoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre (UMMC)</name>
      <address>
        <city>Pantai</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gim Sim Ooi</last_name>
      <phone>+603 7949 2622</phone>
      <email>ooigimsim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Meow Keong Thong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Russian National Research Medical University n.a. N.I.Pirogov, structural branch - Research Clinical Institute of Pediatrics n.a. Academician Yu. E. Veltishchev</name>
      <address>
        <city>Moscow</city>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Artemyeva</last_name>
      <phone>7 916-207-81-53</phone>
      <email>artemievasb@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Dmitry Vlodavets, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun-Hui Chou</last_name>
      <phone>886 972 977 320</phone>
      <email>wendychoucrn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yuh-Jyh Jong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei-Lan Liou</last_name>
      <phone>+866 2 23123456</phone>
      <phone_ext>71618</phone_ext>
      <email>majalis.tw@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wang-Tso Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ptcbio.com</url>
    <description>References</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Dystrophinopathy</keyword>
  <keyword>Nonsense Mutation</keyword>
  <keyword>Premature Stop Codon</keyword>
  <keyword>Becker Muscular Dystrophy</keyword>
  <keyword>DMD/BMD</keyword>
  <keyword>PTC124</keyword>
  <keyword>Ataluren</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Muscular Disorders, Atrophic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

